Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises on Abcam’s US$5.7 billion sale to Danaher. Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a global science and technology innovator, announced...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
You must be a Standard 1 Year member to access this content.
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented P3 Health Partners in the transaction. P3 Health Partners, a patient-centered and physician-led population health management company, has closed its previously announced business combination...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
You must be a Standard 1 Year member to access this content.
